Defibrillator legislation
This article was originally published in The Gray Sheet
Executive Summary
The "Automatic Defibrillation in Adam's Memory Act," S 231, clears the Senate HELP Committee April 2. The bill would "authorize the use of certain grant funds to establish an information clearinghouse that provides information to increase public access to defibrillation in schools." Companion legislation (HR 389) passed the House March 12 (1"The Gray Sheet" March 17, 2003, p. 22)...
You may also be interested in...
Legislation In Brief
Brachyatherapy coverage: Brachytherapy devices would be excluded from the hospital outpatient prospective payment system under bill introduced by Rep. Nathan Deal (R-Ga.) March 11. The bill calls for the number, isotope and radioactive intensity to be paid for separately, including separate groups for palladium-103 and iodine-125, by creating additional groups of outpatient services and classifying them apart from other services. Theragenics (Theraseed palladium-103 seed) and the Coalition for the Advancement of Brachytherapy have been rebuffed repeatedly by CMS in attempts to get the agency to pay for prostate brachytherapy seeds separately, most recently in the 2003 OPPS final rule (1"The Gray Sheet" Nov. 11, 2002, p. 26). HR 1182 was referred to the Energy & Commerce and Ways & Means Committees...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.